A B S T R A C T Chlorozotocin is a chloroethyl nitrosourea with a glucose carrier that has curative activity for the murine L1210 leukemia, but is nonmyelosuppressive in mice. To determine the mechanism for this unique property of reduced bone marrow toxicity, comparative studies were conducted with chlorozotocin and CCNU, a myelotoxic chloroethyl nitrosourea.
Suspensions of L1210 leukemia and murine bone marrow cells were incubated for 2 h with 0.1 mM [14C]-chloroethyl chlorozotocin or CCNU. Chlorozotocin demonstrated a fourfold increased covalent binding of the chloroethyl group to L1210 nuclei when compared to equimolar CCNU. Chlorozotocin alkylation of L1210 cells resulted in the binding of 57 pmol of ['4C ]ethyl group/mg of DNA, which represented a 2.3-fold increased alkylation when compared to CCNU. In marked contrast, the binding of the chloroethyl group to bone marrow nuclei was equivalent for both drugs. In addition, chlorozotocin alkylation of murine bone marrow DNA, 45 pmol of ['4C]ethyl group/mg of DNA, was equivalent to that of CCNU. The ratio of L1210:bone marrow DNA alkylation was 1.3 for chlorozotocin compared to 0.6 for CCNU. The intracellular carbamoylation of L1210 and bone marrow protein by CCNU was 400-to 600-fold greater than that produced by chlorozotocin.
After a 2-h exposure to 0.1, 0.05, or 0.01 mM drug, both chlorozotocin and CCNU produced a reduction in the cloning efficiency of L1210 cells that was dose dependent. However, chlorozotocin was significantly more cytotoxic than CCNU at all three molar concentrations (P < 0.01). Chlorozotocin, 0.1 mM, reduced L1210 DNA synthesis to 1% of control by 48 h, in contrast to 16% with equimolar CCNU (P < 0.01).
In mice bearing 105 L1210 cells, chlorozotocin produced its optimal antitumor activity (332% increased life span [ILS] ) at doses of 48-64 ,tmol/kg, with >50%
INTRODUCTION
The chloroethyl nitrosoureas are an important class of antitumor agents with a broad spectrum of activity in human cancer (1) . However, all of the agents in active clinical use, 1,3-bis(2-chloroethyl)-1-nitrosourea, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU),' and methyl CCNU, produce delayed and cumulative bone marrow depression, which significantly limits their clinical usefulness (2) . Structure-activity studies with the nonmyelosuppressive methyl nitrosourea, streptozotocin, and its cytotoxic group, 1-methyl-l-nitrosourea, suggested that this bone marrow toxicity could be reduced by the attachment of the cytotoxic group to the carbon-2 position of glucose (3) . To evaluate the influence ofthe glucose carrier for the more active chloroethyl nitrosourea class ofcompounds, a new compound, 2-[3-(2-chloroethyl)-3-nitrosoureido]-D-glucopyranose, chlorozotocin, was synthesized for our studies by Johnston et al. (4) . Chlorozotocin has curative antitumor activity for the murine L1210 leukemia and is nonmyelosuppressive in mice (5) .
The mechanism by which the glucose carrier on the nitrosourea cytotoxic group confers the specific protective effect for murine bone marrow remains undetermined. In this report, we compare the quantitative in vitro alkylation and carbamoylation of bone marrow and L1210 leukemia DNA, cytoplasmic RNA, and protein by chlorozotocin and CCNU. These results are correlated with the relative antitumor and myelosuppressive activities of the two nitrosoureas in mice.
METHODS

Animal studies
MIale BALB/C x DBA/2F (CDF,) mice, weighing 17-25 g and maintained on Lab-Blox laboratory chow pellets and water, ad libitum, were used throughout. The chloroethyl nitrosoureas investigated in the study are 2-[3-(2-chloroethyl)-3-nitrosoureido]-D-glycopyranose or chlorozotocin (NSC 178248) and CCNU (NSC 79037); the structures of these two agents are presented in Table I . Both nitrosoureas were supplied by the Drug Development Branch, Div. of Cancer Treatmiient, National Cancer Institute, Bethesda, Md. Chlorozotocin was dissolved in 0.01 M citrate buffer, pH 4, and CCNU was stispended in 5% ethanol, 5% polyoxyethylated vegetable oil, and 90% saline for all the animal studies; each drug was administered intraperitoneally as a single dose in a volume of 0.1 ml/10 g body wt. Radiolabeled chlorozotocin and CCNU were dissolved in these vehicles, respectively, for the in vivo mnurine bone marrow distribution study. All experiments were performed three times.
The murine L1210 leukemia system was used to assess antitumor activity. Treatment was administered to groups of 10 mice as a single dose on the second day after implantation of 1 x 105 L1210 leukemia cells i.p. The percent increased life span (ILS) was calculated from the survival of control tumor-bearing animals that received appropriate volumes of the respective diluents (6) The peak concentration of intact N-nitroso chlorozotocin in mouse plasma was determined after admninistration of an LD10 (20 mg/kg i.p.). The plasma disappearanice of chlorozotocin was followed by measurement of the intact Nnitroso group of the drug using the Forist (7) modification of the Bratton-Marshall reaction. Plasma clearance of intact chlorozotocin was measured in three mice for each of the following time points: 2.5, 5, 7.5, 10, and 15 min after administration. At the appropriate time point, each mouise was anesthetized with ether and a 1-ml sample of blood was obtained by cardiac puncture. Immediately after withdrawal, the 1-ml sample was centrifuged at 8,000 g for 2 min. A 0.4-ml aliquot of the plasma was then added to 0.1 ml of 3 N perchloric acid, vortexed for 10 s, and recentrifuged. In this procedure, the intact N-nitroso group is cleaved to yield nitrous acid in the resulting supernate. A 0.25-ml aliquot of this supernate was added to 0.25 ml of 0.1 mM acetate buffer (pH 4), 2.5 ml ofcolor reagent (0.5% sulfanilic acid and 0.5% N-(1-napthyl)ethylenediamine dihydrochloride in 30% acetic acid), and 0.5 ml of 6 N HCI. This reaction mixture was incubated for 45 min at 60°C; the nitrous acid diazotizes the sulfanilic acid, which then couples to the napthylethylenediamine to form a colored product with an absorbance maximum at 550 nm. A pretreatment blood sample served as a control. The plasma concentration of N-nitroso intact chlorozotocin was calculated from a standard curve that followed Beer's law over a concentration range of 5-250 ,tM. The results in Fig. 1 are presented as the mean+SD of the three values obtained per time point.
Chemical and in vitro cell suspension studies Chemical carbamoylating activity. To measure the chemical carbamoylating activity of each nitrosourea, the following procedure was used: 4.2 ,umol of cold lysine, 0.4 ,uCi of [U-'4C]lysine (Amersham Corp., 300 mCi/mmol sp act), 120 iLl of 0.1 M Na phosphate buffer, pH 7.4, 160 ,ul of ethanol, and 4.2 ,umol of each nitrosourea were incubated together for 6 h at 37°C. The reaction mixture without nitrosourea served as a control. 10 pJ of each reaction mixture were spotted on Whatman No. 3 chromatography paper (Whatman, Inc., Clifton, N. J.) that had been prewetted with 0.1 M Na phosphate buffer, pH 6. Separation was accomplished using a Savant high-voltage flat plate electrophoresis tank (Savant Instruments, Inc., Hicksville, N. Y.) at 3,000 V for 75 min. Radioactivity in 1-inch squares was counted. A distinct peak of radioactivity not associated with the parent [U-_4C]lysine represented products of carbamoylation. The carbamoylated products have previously been identified as a mixture of an a-carbamoyl derivative of lysine, an e-carbamoyl derivative of lysine, and a combined a-carbamoyl and E-carbamoyl derivative of lysine (8, 9) . Carbamoylating activity is expressed as the percentage of the total radioactivity associated with the carbamoylated product (10) .
Chemical alkylating activity. An aliquot with 0.20-4.0 ,umol of each nitrosourea dissolved in acetone was added to 1.5 ml of 5% (wt/vol) 4-(p-nitrobenzyl)pyridine in acetone. 4 ml of 0.025 M acetate buffer, pH 6, were added and the solution was incubated at 37°C for 2 h. 2 ml of acetone and 3 ml of ethyl acetate were then added. The mixture was made aikaline by the addition of 1.5 ml of 0.25 N NaOH, shaken vigorously, and centrifuged at 3,000 rpm for 15 s. The absorbance of the ethyl acetate layer was determined at 540 nm. The relative alkylating activity of CCNU is expressed as a percentage of the activity of chlorozotocin (11) .
In vitro alkylation and carbamoylation of L1210 leukemia and murine bone marrow cells. (12) . To determine the importance of such nonspecific reuse for these studies, [1-14C] chloroethyl chlorozotocin was maintained in phosphate-buffered saline, pH 7.4, in a closed system at 37°C for 5 h. The half-life of chlorozotocin under these conditions is 48 min and at the end of the incubation, there was no intact N-nitroso chlorozotocin as measured by the Forist (7) Isolation of alkylated DNA, RNA, and protein
The extraction of cytoplasmic DNA, RNA, and protein from a single tissue sample was performed by a procedure developed in our laboratory, which is a modification of published methods (13) . This method used whole cells that had been stored at -70°C after the drug incubations as described above. Cytoplasmic RNA was extracted with Na deoxycholate and 154 mM NaCl in the presence of phenol. Na deoxycholate, p-aminosalicylate, and 1 M NaCl with phenol extracted the DNA. The DNA was then freed of RNA with RNase Ti and T2. Cytoplasmic RNA with no detectable DNA and <0.2% protein contamination was obtained. The DNA isolated had <3% uracil compared to thymine and no more than 0.1% protein. As compared to nucleic acids extracted by the method of Schmidt-Thannhauser, the yields of DNA and RNA by this method were 60-70% and 50-60%, respectively, for both L1210 leukemia and murine bone marrow cells (13) . Approximately 3% of added radiolabeled drug was covalently incorporated into cells.
The concentrations of DNA and RNA were determined by the diphenylamine and orcinol methods, respectively (14, 15 The nuclear pellet was subjected to phase microscopy to ensure that it was free of significant cytoplasmic strands. Once isolated, the cytoplasmic fraction was precipitated with 3 vol of absolute ethanol. Both fractions were washed twice with 70% ethanol and 0.1 M Na acetate. Residual radioactivity was counted after each wash and a steady state was achieved after the second wash. Each fraction was then dissolved in 1 ml of 1 N NaOH over a period of 3 d. The protein concentration was determined by the method of Lowry et al. (17) . The radioactivity in a 0. (20) . Radioactivity in a 0.5-ml aliquot of the supernate was measured. An additional 0.5-ml aliquot of the supernate was used for the measurement of DNA concentration by the diphenylamine method (14) (Table IV) . Compared to equimolar CCNU, there was an eightfold increased covalent binding of the ethyl group of chlorozotocin to the cytoplasmic fraction of L1210 cells and a fourfold increased binding to the nuclear fraction. In contrast, in bone marrow cells there was a threefold increased covalent binding of chlorozotocin to the cytoplasmic fraction, but the binding to the nuclear fraction was equivalent for the two drugs.
Comparable studies were conducted with L1210 cells in the presence of the protein synthesis inhibitor cycloheximide, to prevent the nonspecific reuse of nitrosourea decomposition products. With conditions similar to the in vitro alkylation experiments.
Chlorozotocin at a concentration of 0.1 mM suppressed DNA synthesis to 7% ofcontrol at 24 h and 1% ofcontrol at 48 h. CCNU suppressed DNA synthesis to 23% of control at 24 h and 16% of control at 48 h. Chlorozotocin is significantly more cytotoxic to L1210 cells than equimolar CCNU at both time points (P < 0.01).
The colony-forming ability of L1210 cells was determined after a 2-h exposure to 0.1, 0.05, or 0.01 mM chlorozotocin or CCNU, and a concentration dependent cytotoxicity was found for both drugs (Fig. 2) . At the maximum drug concentration employed, 0.1 mM, chlorozotocin reduced the cloning efficiency by 5.3 logs compared to a reduction by 4.8 logs for equimolar CCNU. At all three molar concentrations, the chlorozotocin-treated cells showed a statistically significant increased cytotoxicity when compared to the CCNU treated cells (P < 0.01).
To correlate in vitro L1210 alkylation with in vivo L1210 antitumor activity, the two nitrosoureas were administered as a single intraperitoneal dose on day 2 to mice bearing intraperitoneally implanted L1210 leukemia (Table V) . Chlorozotocin, at its LD,o of64 ,umol/kg, resulted in a 332% ILS compared to untreated tumorbearing mice, with 60% indefinite survivors. CCNU administered at this same molar dose resulted in only a 191% ILS, with 20% indefinite survivors (P < 0.05). The optimal therapeutic dose of chlorozotocin, 48-64 ,umol/kg, was one-third to one-half the molar dose of CCNU, 128 ,umol/kg, required for comparable antileukemic activity. There was no statistically significant difference in the maximal antitumor activity of these two nitrosoureas when administered at their respective optimal molar doses.
To correlate in vitro alkylation of murine bone marrow with in vivo myelotoxicity, the total WBC count (2) . Chlorozotocin, a new glucose-containing nitrosourea, was designed to selectively reduce this toxicity for the bone marrow (4, 5) . This agent demonstrates curative antitumor activity for the murinie L1210 leukemia. At optimal therapeutic doses, however, there was no evidence of myelosuppression as indicated by normal neutrophil counts, bone marrow histology, and DNA synthesis, and survival of murine granulocyte precursor cells (CFU-C) (23, 24) . In our recently completed phase I clinical trial of the drug, a single dose of 120 mg/M2 resulted in peak plasma drug concentrations of 0.1 mM (24, 25) . It is of importance to the present study that the optimal L1210 antitumor dose of chlorozotocin in mice, 64 ,umol/kg, also produced a peak plasma concentration of 0.1 mM. At the 120 mg/M2 dose of chlorozotocin in man, objective responses were observed in patients with melanoma, colon cancer, and lymphoma (24, 25) . Moreover, there was no leukopenia or thrombocytopenia in patients who had not received extensive prior chemotherapy, and there has been no evidence of cumulative bone marrow toxicity (25) .
Under physiological conditions, the chloroethyl nitrosoureas decompose to yield chloroethyl carbonium ions, or diazonium precursors, which are the principal alkylating products (26) . In addition, organic isocyanates are generated which carbamoylate the lysine moieties and the terminal amino groups of peptides and proteins (8, 27) . In the present study, CCNU was found to have significant carbamoylating activity as measured by the [14C]lysine assay. In the murine cell culture systems, CCNU carbamoylated protein 400-to 600-fold greater than chlorozotocin. However, the latter compound's excellent antitumor activity is not adversely affected by its negligible carbamoylating activity.
In our previous structure-activity studies using linear regression analyses, we have failed to demonstrate a significant correlation for in vitro carbamoylating activity with either antitumor activity, myelosuppression, or lethal toxicity. In contrast, the same analyses have demonstrated that a glucose carrier for the cytotoxic group is a specific parameter that correlates with reduced murine bone marrow toxicity (9, 10, (28) (29) (30) . As an important example, ACNU is a pyrimidine analogue that has chemical properties similar to chlorozotocin, including water solubility and negligible carbamoylating activity. In contrast to the latter glucose analogue, ACNU is a potent myelotoxin in both mouse and man (29) . 1-(2-chloroethyl)-3-(B-D-glucopyranosyl)-l-nitrosourea (GANU) is a second glucose chloroethyl nitrosourea that has reduced murine myelotoxicity (10, 30) . With chlorozotocin, the cytotoxic group is attached to the carbon-2 of glucose, whereas attachmeint is at carbon-I with GANU. GANU, unlike chlorozotocin, has significant chemical carbamoylating activity equivalent to the myelosuppressive nitrosourea BCNU, but produced no bone marrow toxicity in mice when administered at a comparable LDIo (10, 30) . Collectively, these data strongly suggest that nitrosourea carbamoylating activity makes little if any contribution to the myelotoxicity of this class of alkylating agents.
The covalent binding of the ['4C]ethyl group of chlorozotocin to L1210 DNA, after a 2-h in vitro incubation, was 2.3-fold greater than that of CCNU at an equimolar dose of 0.1 mM. This concentration of chlorozotocin produced a fourfold increased covalent binding to the nuclear fraction of L1210 cells in vitro as compared to equimolar CCNU. In marked contrast to the results with L1210 cells, the in vitro alkylation of murine bone marrow DNA was eqjuivalent for the two drugs at this 0.1 mnl concentration. The in vitro covalent binding to the nuclear fraction of the marrow cells was also equivalent. In these experiments, the ratio of alkylation of L1210:bone marrow DNA was 1.3 for chlorozotocin comupared to 0.6 for CCNU. It must be acknowledged that these results were obtained using our phenol method of extraction, which recovers 60-70% of the DNA. XVhile the results are consistent in all experiments, it is possible that a more efficient extraction procedure might alter these results. The greater in vitro alkylation of L1210 DNA by chlorozotocin as compared to CCNU has biological significance. The optimal in vivo antitumor activity of chlorozotocin against the L1210 leukemia, 332% ILS, was achieved at doses of 48-64 ,umol/kg. In comparison, CCNU administered at these same molar doses produced only a 191% ILS, and the dose of CCNU required for comparable optimal L1210 antitumor activity was 128 ,umol/kg. As a correlate, in the in vitro cloning assay, L1210 cells treated with 0.1, 0.05, or 0.01 mM chlorozotocin for 2 h showed significantly increased cytotoxicity when compared to cells treated with equimolar CCNU (P < 0.01). In similar experiments measuring the cloning efficiency of L1210 cells after a 1-h exposure to drug, Kann (31) has reported that chlorozotocin was significantly more cytotoxic than CCNU at comparable drug concentrations.
To measure differences in the distribution of the two drugs in vivo, the (quantitative covalent binding of the ethyl-labeled drugs to nucleated bone marrow cells was determined at 60 min after intraperitoneal injection. Chlorozotocin was administered at its optimal L1210 antitumor dose of 64 ,umol/kg. For comparison, CCNU was administered at its optimal L1210 antitumor dose of 128 unmol/kg and at the 64 umol/kg dose. At the equimolar dose (64 ,umol/kg), there was no significant difference in the picomoles of ['4C]ethyl group covalently bounid per 107 nucleated marrow cells, 6.6 pmol for chlorozotocin and 5.6 pmol for CCNU (P > 0.10). In comiiparison, the covalent binding of the [14C]ethyl group of CCNU per 107 marrow cells was significantly greater, 9.5 pmol, at its optimal L1210 antitumor dose of 128 ,umol/kg (P < 0.01).
In conclusion, chlorozotocin has curative antitumor activity for the L1210 leukemia comparable to CCNU, but at one-third to one-half the molar dose of the latter compound. Chlorozotocin, unlike CCNU, produces no murine bone miarrow toxicity at its optimal therapeutic dose. This uni(lue combination of antitumor activity without myelosuppression can be correlated with the advantageous ratio of L1210:bone marrow DNA alkylation by chlorozotocin as comnpared to equimolar CCNU, in vitro.
